Search

Physicians and researchers at MSK Kids, Memorial Sloan Kettering Cancer Center’s dedicated pediatric cancer program, completed several groundbreaking research studies in 2023. These studies, which focused on pediatric disease mechanisms, paved the way to promising new therapeutic approaches for improving patient outcomes.

… Tuesday, December 26, 2023 Physicians and researchers at  MSK Kids , Memorial Sloan Kettering Cancer Center’s dedicated pediatric cancer program, completed several groundbreaking research studies in 2023. These studies, which focused on pediatric disease mechanisms, paved the way to promising new therapeutic

In 1971, Richard Nixon launched a “war on cancer.” It’s still raging.

… Wednesday, January 1, 2020 In 2016, when Vice President Joseph Biden announced the “Cancer Moonshot” initiative , many in the scientific world felt a twinge of déjà vu. This wasn’t the first time that officials in the US government had set their sights on an ambitious plan to conquer cancer. In fact,

By switching from one cellular identity to another, lung cancer cells can evade targeted therapies. MSK scientists are trying to stop that from happening.

… Thursday, October 28, 2021 For people with lung cancer , drug resistance is the major cause of relapse. A tumor might respond very well at first — maybe even shrinking down to an undetectable level — only to develop resistance and grow back. Scientists are learning that one of the ways that lung cancers

Learn how genetic analysis of prostate cancer tumors is guiding treatment with checkpoint inhibitor immunotherapy.

… Friday, October 24, 2025 Immunotherapy drugs called  checkpoint inhibitors  are a promising cancer treatment, but so far only a minority of people respond to them. This has been especially notable in the treatment of  prostate cancer , the most common cancer in men, after skin cancer. Researchers at

Discover where three recent Gerstner Sloan Kettering graduates are now and learn about the research they’re pursuing.

… Tuesday, September 20, 2016 Gerstner Sloan Kettering graduate James Mahaffey works in a lab at the Perlmutter Cancer Center at NYU School of Medicine exploring the RAS gene, which is mutated in nearly a third of cancers but has resisted targeting with drugs. James Mahaffey studies RAS, a gene that is

Memorial Sloan Kettering’s suburban presence is expanding with its newest and largest state-of-the-art facility set to welcome patients on October 6 in West Harrison, New York.

… Wednesday, October 1, 2014 VIDEO | 04:30 Virtual Tour of Memorial Sloan Kettering Cancer Center Westchester Take a virtual tour of our suburban outpatient location and hear from our doctors on the benefits of receiving care at MSK Westchester. Video Details Memorial Sloan Kettering’s suburban presence

Experiments with zebrafish and human pluripotent stem cells reveal the necessary ingredients, besides genetic mutations, that fuel the development of melanoma.

… Friday, September 3, 2021 Right now, in your body, lurk thousands of cells with DNA mistakes that could cause cancer. Yet only in rare instances do these DNA mistakes, called genetic mutations, lead to a full-blown cancer. Why? The standard explanation is that it takes a certain number of genetic “hits

… Tuesday, December 2, 2025 Memorial Sloan Kettering Cancer Center (MSK) today announced the following awards and appointments: Omar Abdel-Wahab Elected to the National Academy of Medicine (NAM) Omar Abdel-Wahab Omar Abdel-Wahab, MD , Chair of the Molecular Pharmacology Program at Sloan Kettering Institute

Justin Perry, PhD, cell biologist and immunologist of Memorial Sloan Kettering’s (MSK) Sloan Kettering Institute (SKI) has been named a recipient of the 2021 National Institutes of Health (NIH) Director’s New Innovator Award.

… Tuesday, October 5, 2021 Justin Perry, PhD , cell biologist and immunologist of Memorial Sloan Kettering’s (MSK) Sloan Kettering Institute (SKI) has been named one of 64 recipients of the prestigious 2021 National Institutes of Health (NIH) Director’s New Innovator Award . As part of the award, Dr. Perry

Learn how multiple myeloma prognosis has improved significantly with the emergence of new drug treatments.

… Tuesday, January 27, 2026 Note: This story was originally published in 2022 and has been updated. Saad Usmani, MD , a hematologic oncologist specializing in multiple myeloma , is Chief of the Myeloma Service at Memorial Sloan Kettering Cancer Center (MSK). Dr. Usmani has more than 15 years of experience